WO2002012188B1 - Composes indoliques utilises dans le traitement du cancer - Google Patents

Composes indoliques utilises dans le traitement du cancer

Info

Publication number
WO2002012188B1
WO2002012188B1 PCT/US2001/024978 US0124978W WO0212188B1 WO 2002012188 B1 WO2002012188 B1 WO 2002012188B1 US 0124978 W US0124978 W US 0124978W WO 0212188 B1 WO0212188 B1 WO 0212188B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cells
lower alkyl
cancer
agent
Prior art date
Application number
PCT/US2001/024978
Other languages
English (en)
Other versions
WO2002012188A3 (fr
WO2002012188A2 (fr
Inventor
Dennis A Carson
Lorenzo M Leoni
Howard B Cottam
Original Assignee
Univ California
Dennis A Carson
Lorenzo M Leoni
Howard B Cottam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/634,207 external-priority patent/US7151100B1/en
Application filed by Univ California, Dennis A Carson, Lorenzo M Leoni, Howard B Cottam filed Critical Univ California
Priority to AU8322401A priority Critical patent/AU8322401A/xx
Priority to AU2001283224A priority patent/AU2001283224B2/en
Priority to JP2002518166A priority patent/JP2004518615A/ja
Priority to EP01962006A priority patent/EP1307459A2/fr
Priority to CA002419060A priority patent/CA2419060A1/fr
Publication of WO2002012188A2 publication Critical patent/WO2002012188A2/fr
Publication of WO2002012188A3 publication Critical patent/WO2002012188A3/fr
Publication of WO2002012188B1 publication Critical patent/WO2002012188B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux dérivés indoliques utilisés pour inhiber le développement du cancer ou sensibiliser les cellules cancéreuses à des agents chimiothérapeutiques, au rayonnement ou à d'autres traitements contre le cancer.
PCT/US2001/024978 2000-08-09 2001-08-09 Composes indoliques utilises dans le traitement du cancer WO2002012188A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU8322401A AU8322401A (en) 2000-08-09 2001-08-09 Indole compounds useful for the treatment of cancer
AU2001283224A AU2001283224B2 (en) 2000-08-09 2001-08-09 Indole compounds useful for the treatment of cancer
JP2002518166A JP2004518615A (ja) 2000-08-09 2001-08-09 癌の処置に有用なインドール化合物
EP01962006A EP1307459A2 (fr) 2000-08-09 2001-08-09 Composes indoliques utilises dans le traitement du cancer
CA002419060A CA2419060A1 (fr) 2000-08-09 2001-08-09 Composes indoliques utilises dans le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/634,207 US7151100B1 (en) 1999-07-23 2000-08-09 Indole compounds useful for the treatment of cancer
US09/634,207 2000-08-09

Publications (3)

Publication Number Publication Date
WO2002012188A2 WO2002012188A2 (fr) 2002-02-14
WO2002012188A3 WO2002012188A3 (fr) 2002-10-03
WO2002012188B1 true WO2002012188B1 (fr) 2003-03-20

Family

ID=24542833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024978 WO2002012188A2 (fr) 2000-08-09 2001-08-09 Composes indoliques utilises dans le traitement du cancer

Country Status (5)

Country Link
EP (1) EP1307459A2 (fr)
JP (1) JP2004518615A (fr)
AU (2) AU2001283224B2 (fr)
CA (1) CA2419060A1 (fr)
WO (1) WO2002012188A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002555A1 (fr) 1998-07-09 2000-01-20 Nardella Francis A Procedes et compositions pour le traitement de la leucemie lymphocitaire chronique
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US7211599B2 (en) 2002-09-19 2007-05-01 The Regents Of The University Of California Use of etodolac to treat hyperplasia
WO2005033112A2 (fr) * 2003-10-02 2005-04-14 Cephalon, Inc. Derives d'indole substitues
FR2869231B1 (fr) * 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EA201892766A1 (ru) * 2011-10-19 2019-08-30 Фармасайкликс Элэлси ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk)
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
WO2015143400A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Mutations de phospholipase c gamma 2 et associées aux résistances

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974179A (en) * 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3843681A (en) * 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
EP0289262A3 (fr) * 1987-04-27 1989-05-31 Syntex Pharmaceuticals International Limited Alkylesters d'ammonium quaternaire-oméga et thioesters de médicaments antiinflammatoires acides non stéroiques
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease

Also Published As

Publication number Publication date
JP2004518615A (ja) 2004-06-24
EP1307459A2 (fr) 2003-05-07
WO2002012188A3 (fr) 2002-10-03
CA2419060A1 (fr) 2002-02-14
AU2001283224B2 (en) 2007-06-28
WO2002012188A2 (fr) 2002-02-14
AU8322401A (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2002012188B1 (fr) Composes indoliques utilises dans le traitement du cancer
TWI674111B (zh) 藥物傳送結合物、治療由表現ｐｓｍａ之細胞所引起疾病之方法
Stearns et al. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases
JPH06502168A (ja) アンギオテンシン２アンタゴニスト
KR20080013997A (ko) 종양 치료용 조성물 및 방법
AU1916401A (en) Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
ES2586655T3 (es) (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer
KR100777195B1 (ko) 송달성 물질 및 이를 이용한 약물 송달 시스템
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
JPH07508000A (ja) １，２，３−トリアゾール及びイミダゾール化合物並びにそれらの抗腫瘍用途
EP3946320A1 (fr) Conjugués liés à hsp90 et formulations de ceux-ci
TW202005667A (zh) Ｈｓｐ９０－靶向共軛體及其調合物
CN114760998A (zh) 用于治疗神经毒性的方法和材料
US9422224B2 (en) Methods of treatment using a BCAT1 inhibitor
RU2004135307A (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
US20210161911A1 (en) Methods of treating cancer
CA2098593C (fr) Methode de traitement du cancer
WO2020096486A1 (fr) Utilisation de 3-o-sulfamate 16,16-diméthyl-d-homequilenine pour traiter des maladies cancéreuses
US20040116496A1 (en) Asymmetric Disulfides and methods of using same
CN113164631A (zh) 治疗癌症的方法
US9173889B2 (en) Heparin-based compositions and methods for the inhibition of metastasis
GALIN et al. Nonsurgical removal of corneal rust stains
RU2811406C2 (ru) Способы лечения рака
WO2009062128A2 (fr) Thérapie par combinaison de médicaments pour le traitement d'un cancer
WO2000021941A1 (fr) Agents et methodes de chelation biomimetique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001283224

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002518166

Country of ref document: JP

Ref document number: 2419060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001962006

Country of ref document: EP

B Later publication of amended claims
WWP Wipo information: published in national office

Ref document number: 2001962006

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001962006

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001283224

Country of ref document: AU